Which of the following is NOT a feature of primary hyperaldosteronism?
Which of the following statements regarding the treatment of hypothyroidism in a patient with ischemic heart disease is true?
What is the most common organ involved in Multiple Endocrine Neoplasia type I?
An adult patient weighing 70 kg has a fasting blood sugar of 180 mg/dl. What is the most likely condition?
Peripheral nerve involvement, presenting as pain, paresthesia, motor weakness, and reflex loss, develops in a significant percentage of patients with which of the following conditions?
In Conn's syndrome, which of the following is true?
A 46-year-old woman with hypertension and diabetes mellitus type II presents with elevated blood pressure despite diet and exercise. She is taking metformin for her diabetes. Her vital signs are: temperature 37°C (98.6°F), blood pressure 146/72 mmHg, pulse 76/min, respirations 16/min, and oxygen saturation 98% on room air. Which of the following medications is most likely to be prescribed?
Which of the following is a microvascular complication of diabetes mellitus?
Metabolic syndrome consists of all of the following, EXCEPT:
Which of the following is NOT a feature of glucocorticoid deficiency?
Explanation: Primary Hyperaldosteronism (Conn’s Syndrome) is characterized by the autonomous overproduction of aldosterone, typically due to an adrenal adenoma or bilateral adrenal hyperplasia. **Why Hyperkalemia is the Correct Answer:** Aldosterone acts on the principal cells of the renal collecting ducts to increase the reabsorption of sodium and the **secretion of potassium and hydrogen ions** into the urine [1]. Consequently, excessive aldosterone leads to **hypokalemia**, not hyperkalemia [3]. Therefore, hyperkalemia is the "odd one out" and the correct answer. **Analysis of Other Options:** * **Hypertension:** Increased sodium reabsorption leads to water retention and expansion of extracellular fluid volume, resulting in hypertension [2]. Notably, this is often resistant to standard therapy. * **Hypokalemia:** As explained, increased renal potassium excretion leads to low serum potassium levels [3]. This can manifest as muscle weakness or cardiac arrhythmias. * **Polyuria:** Chronic hypokalemia can cause "hypokalemic nephropathy," which impairs the kidney's ability to concentrate urine (nephrogenic diabetes insipidus), leading to polyuria and polydipsia. **High-Yield Clinical Pearls for NEET-PG:** * **Screening Test:** Plasma Aldosterone Concentration (PAC) to Plasma Renin Activity (PRA) ratio. A ratio **>20-30** is highly suggestive. * **Confirmatory Test:** Oral or Intravenous Salt Loading Test (failure to suppress aldosterone). * **Metabolic State:** Patients typically exhibit **Metabolic Alkalosis** (due to $H^+$ loss) [1], [3]. * **Aldosterone Escape:** Edema is usually absent in primary hyperaldosteronism because of "atrial natriuretic peptide (ANP) mediated diuresis," which prevents massive fluid overload [2].
Explanation: ### Explanation **Core Concept:** In patients with hypothyroidism and concurrent **Ischemic Heart Disease (IHD)**, thyroid hormone replacement must be initiated with extreme caution. Levothyroxine increases the metabolic rate, oxygen consumption, and myocardial contractility [1]. In a heart with compromised coronary circulation, a sudden increase in cardiac demand can precipitate **angina, myocardial infarction, or fatal arrhythmias.** [1] **Why Option A is Correct:** The standard protocol for elderly patients or those with IHD is to **"Start Low and Go Slow."** The typical starting dose is **12.5 to 25 µg/day**, which is significantly lower than the standard replacement dose [2]. The dose is then titrated upwards in small increments every 4–6 weeks based on clinical response and TSH levels to allow the myocardium to adapt to the increased metabolic demand [2]. **Why Other Options are Incorrect:** * **Option B (Normal dose):** A full replacement dose (approx. 1.6 µg/kg) can cause a rapid increase in heart rate and stroke volume, potentially leading to an acute coronary syndrome or heart failure [2]. * **Option C (Do not use):** Untreated hypothyroidism itself worsens cardiovascular risk factors (dyslipidemia, hypertension) and can lead to myxedema coma. Treatment is necessary but must be cautious. * **Option D (Thyroid extract):** Desiccated thyroid extracts contain T3, which has a rapid onset and can cause "peaks" in hormone levels, making it much more dangerous for the heart than the stable T4 (Levothyroxine). **High-Yield Clinical Pearls for NEET-PG:** * **Standard Starting Dose (Healthy Adult):** 1.6 µg/kg/day. * **Starting Dose (IHD/Elderly):** 12.5–25 µg/day [2]. * **Monitoring:** TSH is the gold standard; check 6–8 weeks after any dose adjustment [2]. * **Drug Interaction:** Levothyroxine increases the effect of Warfarin (monitor PT/INR) and may require an increase in Insulin/Oral Hypoglycemic doses.
Explanation: **Explanation:** **Multiple Endocrine Neoplasia type 1 (MEN1)**, also known as Wermer’s syndrome, is an autosomal dominant disorder caused by a mutation in the *MEN1* gene (encoding the protein Menin). It is classically characterized by the "3 Ps": **P**arathyroid, **P**ancreas, and **P**ituitary. **Why Parathyroid is correct:** Primary Hyperparathyroidism (PHPT) is the **most common** and often the **earliest** clinical manifestation of MEN1, occurring in over **95% of patients** by age 40. Unlike sporadic cases which usually involve a single adenoma, MEN1-associated hyperparathyroidism typically involves **multiglandular hyperplasia**. **Why other options are incorrect:** * **B. Thyroid:** While thyroid adenomas or goiters can occasionally be seen in MEN1 patients, they are not a defining feature of the syndrome. Medullary thyroid carcinoma is a hallmark of MEN 2A and 2B, not MEN 1. * **C. Adrenal:** Adrenal cortical lesions (like bilateral hyperplasia or adenomas) occur in about 20-40% of MEN1 cases but are significantly less common than parathyroid involvement and are often non-functional. * **D. Testis:** Testicular tumors are not a standard component of the MEN1 clinical triad. **High-Yield Clinical Pearls for NEET-PG:** * **The 3 Ps of MEN1:** Parathyroid (95%), Pancreatic Islet cells (e.g., Gastrinoma/Zollinger-Ellison Syndrome - 40-70%), and Anterior Pituitary (e.g., Prolactinoma - 30-40%). * **Most common Pancreatic tumor in MEN1:** Gastrinoma (though Insulinomas are also frequent). * **Screening:** If a patient presents with multiglandular parathyroid disease at a young age, always screen for MEN1. * **Cutaneous markers:** Look for facial angiofibromas, collagenomas, and lipomas, which are common non-endocrine findings in MEN1.
Explanation: The patient presents with a fasting blood sugar (FBS) of **180 mg/dl**, which is significantly higher than the normal physiological range. According to the American Diabetes Association (ADA) criteria, a fasting plasma glucose level of **≥126 mg/dl** is diagnostic of Diabetes Mellitus [1]. Therefore, the most accurate description of this biochemical state is **Hyperglycemia** [2]. **Analysis of Options:** * **Hyperglycemia (Correct):** Defined as an elevation in blood glucose levels [2]. In a 70 kg adult, the normal fasting range is typically 70–100 mg/dl. A value of 180 mg/dl confirms hyperglycemia. * **Ketoacidosis (Incorrect):** While Diabetic Ketoacidosis (DKA) involves hyperglycemia, it is a complex metabolic triad consisting of hyperglycemia, ketonemia, and metabolic acidosis (pH <7.3). We cannot diagnose DKA based on a glucose reading alone without clinical signs (Kussmaul breathing, fruity breath) and lab evidence of ketones/acidosis [3]. * **Hypoglycemia (Incorrect):** This refers to abnormally low blood glucose, typically defined as <70 mg/dl in diabetic patients or <55 mg/dl in non-diabetic individuals. * **Thyroidism (Incorrect):** This is a vague term. While hyperthyroidism can cause secondary hyperglycemia (due to increased glycogenolysis), it is a thyroid disorder, not a description of a blood glucose level. **NEET-PG High-Yield Pearls:** 1. **Diagnostic Criteria for Diabetes:** * FBS ≥ 126 mg/dl [1] * 2-hour Post-Prandial (OGTT) ≥ 200 mg/dl * HbA1c ≥ 6.5% * Random Blood Sugar ≥ 200 mg/dl with symptoms of polyuria/polydipsia. 2. **Prediabetes:** FBS between 100–125 mg/dl (Impaired Fasting Glucose) [1]. 3. **Renal Threshold for Glucose:** Glucose starts appearing in urine (glycosuria) when blood levels exceed **180 mg/dl** [3].
Explanation: **Explanation:** **Diabetes Mellitus (DM)** is the most common cause of peripheral neuropathy worldwide. The pathogenesis involves chronic hyperglycemia leading to the accumulation of sorbitol (via the polyol pathway), advanced glycation end-products (AGEs), and increased oxidative stress. These factors cause microvascular damage to the *vasa nervorum*, leading to nerve ischemia. The classic presentation is a **Symmetric Distal Sensorimotor Polyneuropathy** ("stocking-and-glove" distribution), characterized by pain, paresthesia, loss of vibration/proprioception, and diminished deep tendon reflexes (especially the ankle jerk). **Why other options are incorrect:** * **Hypoparathyroidism:** Primarily presents with features of hypocalcemia, such as tetany, carpopedal spasm, and seizures. While it causes neuromuscular irritability (Chvostek/Trousseau signs), it does not typically cause structural peripheral nerve degeneration or motor weakness. * **Adrenal Insufficiency:** Presents with hypotension, hyperpigmentation, and electrolyte imbalances (hyponatremia, hyperkalemia). It does not involve peripheral nerve pathology. * **Hyperthyroidism:** More commonly associated with **proximal myopathy** (weakness of hip/shoulder girdles) rather than peripheral neuropathy. Reflexes in hyperthyroidism are characteristically "brisk" or hyperreflexic, not lost. **High-Yield Clinical Pearls for NEET-PG:** * **Mononeuritis Multiplex:** DM is a leading cause; it involves the involvement of two or more non-contiguous nerve trunks. * **Diabetic Amyotrophy:** A plexopathy presenting as severe pain followed by weakness and wasting of the proximal thigh muscles. * **Cranial Nerve Involvement:** The **3rd Cranial Nerve** is most commonly affected in DM, typically presenting with **pupillary sparing** (due to ischemic rather than compressive injury).
Explanation: In Conn’s syndrome, which of the following is true? **Conn’s Syndrome (Primary Hyperaldosteronism)** is characterized by the autonomous overproduction of aldosterone, typically due to an adrenal adenoma. ### **Explanation of the Correct Option** **A. Patients most often have elevated blood pressure:** This is the hallmark of the condition. Aldosterone acts on the principal cells of the renal collecting ducts to increase sodium reabsorption and water retention, leading to volume expansion and **secondary hypertension**. Notably, Conn’s syndrome is a leading cause of secondary hypertension and should be suspected in patients with treatment-resistant high blood pressure [2]. ### **Why Other Options are Incorrect** * **B. The usual treatment involves managing blood pressure and most symptoms:** This is incorrect because the "usual" or definitive treatment for Conn’s syndrome (unilateral adenoma) is **surgical (Laparoscopic Adrenalectomy)**. Medical management with mineralocorticoid receptor antagonists (e.g., Spironolactone) is reserved for bilateral adrenal hyperplasia or patients unfit for surgery [1]. * **C. Muscle twitching is not typically associated with this condition:** This is incorrect. Aldosterone causes potassium excretion (hypokalemia). Severe hypokalemia leads to increased neuromuscular irritability, manifesting as **muscle twitching, cramps, paresthesia, and even tetany**. ### **NEET-PG High-Yield Pearls** * **Classic Triad:** Hypertension, Hypokalemia, and Metabolic Alkalosis. * **Screening Test:** Plasma Aldosterone Concentration (PAC) to Plasma Renin Activity (PRA) ratio. A **PAC:PRA ratio > 20-30** is highly suggestive. * **Confirmatory Test:** Saline infusion test or Oral salt loading test (failure to suppress aldosterone). * **Localization:** CT scan of the adrenals is the initial imaging; **Adrenal Venous Sampling (AVS)** is the gold standard to differentiate unilateral from bilateral disease [1].
Explanation: **Explanation:** The correct answer is **Lisinopril (Option C)**. **Why Lisinopril is the drug of choice:** In patients with **Diabetes Mellitus and Hypertension**, ACE inhibitors (like Lisinopril) or ARBs are the first-line antihypertensive agents. The underlying medical concept is **renoprotection**. ACE inhibitors reduce intraglomerular pressure by dilating the efferent arteriole, thereby slowing the progression of diabetic nephropathy and reducing albuminuria. Even in the absence of overt proteinuria, they are preferred in diabetics to prevent chronic kidney disease (CKD). **Why the other options are incorrect:** * **Amlodipine (Option A):** While Calcium Channel Blockers (CCBs) are effective antihypertensives, they do not offer the same level of renal protection as ACE inhibitors in diabetic patients. They are typically used as second-line or add-on therapy. * **Furosemide (Option B):** Loop diuretics are primarily used for fluid overload states (e.g., heart failure, edema) rather than primary hypertension management, unless the patient has advanced CKD (GFR <30). * **Spironolactone (Option D):** This potassium-sparing diuretic is generally reserved for resistant hypertension or primary aldosteronism. It is not a first-line agent for uncomplicated diabetic hypertension. **Clinical Pearls for NEET-PG:** * **Target BP in Diabetes:** According to most guidelines (ADA/JNC), the target is generally **<130/80 mmHg**. * **Monitoring:** Always check serum **creatinine and potassium** levels within 1-2 weeks of starting an ACE inhibitor. A rise in creatinine up to 30% is acceptable. * **Contraindication:** ACE inhibitors are strictly **contraindicated in pregnancy** (teratogenic) and in patients with bilateral renal artery stenosis. * **Side Effect:** The most common side effect of ACE inhibitors is a **dry cough** (due to bradykinin accumulation); if this occurs, switch the patient to an ARB (e.g., Losartan).
Explanation: Chronic hyperglycemia in diabetes mellitus leads to vascular damage categorized into two main types: **Microvascular** (affecting small capillaries) and **Macrovascular** (affecting large arteries) [1]. **Why Retinopathy is Correct:** Diabetic retinopathy is the classic hallmark of **microvascular** disease. It occurs due to basement membrane thickening, loss of pericytes, and increased capillary permeability in the retinal vessels [1]. This leads to microaneurysms, hemorrhages, and neovascularization [3]. Other primary microvascular complications include **Nephropathy** and **Neuropathy**. **Analysis of Incorrect Options:** * **Coronary circulation (B):** This is a **macrovascular** complication. Macrovascular disease involves atherosclerosis of large vessels, leading to Coronary Artery Disease (CAD), Stroke (Cerebrovascular disease), and Peripheral Arterial Disease (PAD) [1]. * **Peripheral (A) and Autonomic (D) Neuropathy:** While these are microvascular in origin (due to ischemia of the *vasa nervorum*), in the context of standard medical examinations and the "classic triad" of diabetic complications, **Retinopathy, Nephropathy, and Neuropathy** are all microvascular [1], [4]. However, if a single best answer must be chosen among these, Retinopathy is the most direct clinical manifestation of small-vessel damage. *Note: In many MCQ formats, if multiple microvascular options are present, the question may be flawed or looking for the "most" characteristic one.* **High-Yield Clinical Pearls for NEET-PG:** * **Earliest sign of Nephropathy:** Microalbuminuria (30–300 mg/day). * **Earliest sign of Retinopathy:** Microaneurysms [3]. * **Kimmelstiel-Wilson (KW) lesions:** Pathognomonic for diabetic nephropathy (nodular glomerulosclerosis). * **Metabolic Memory:** Early glycemic control prevents long-term microvascular complications even if control worsens later [2].
Explanation: **Explanation:** Metabolic syndrome (also known as Syndrome X or Insulin Resistance Syndrome) is a cluster of metabolic abnormalities that significantly increase the risk of cardiovascular disease and Type 2 Diabetes Mellitus [1]. The diagnosis is most commonly based on the **NCEP ATP III criteria**. **Why High LDL is the correct answer:** While elevated LDL (Low-Density Lipoprotein) is a major risk factor for atherosclerosis [1], it is **not** a diagnostic component of Metabolic Syndrome. The lipid abnormalities specific to this syndrome are **Hypertriglyceridemia** and **Low HDL cholesterol** [1]. This distinction is a frequent "trap" in postgraduate exams. **Analysis of other options:** * **High blood pressure (Option A):** A core component. Defined as BP ≥130/85 mmHg or being on antihypertensive medication. * **Low HDL cholesterol (Option C):** A core component. Defined as <40 mg/dL in men or <50 mg/dL in women [1]. * **Increased abdominal circumference (Option D):** Central obesity is a hallmark. Defined as >102 cm (40 in) in men or >88 cm (35 in) in women (Note: Cut-offs are lower for South Asians: >90 cm for men, >80 cm for women). **High-Yield Clinical Pearls for NEET-PG:** 1. **NCEP ATP III Criteria:** Diagnosis requires **3 out of 5** of the following: * Abdominal obesity * Triglycerides ≥150 mg/dL * HDL <40 (M) / <50 (F) mg/dL * BP ≥130/85 mmHg * Fasting Glucose ≥100 mg/dL 2. **Pathophysiology:** The primary underlying mechanism is **Insulin Resistance**. 3. **Acanthosis Nigricans:** Often seen clinically as a cutaneous marker of the underlying insulin resistance.
Explanation: ### Explanation The key to answering this question lies in distinguishing between **isolated glucocorticoid deficiency** (secondary adrenal insufficiency) and **combined mineralocorticoid and glucocorticoid deficiency** (primary adrenal insufficiency/Addison’s disease). **Why Hyperkalemia is the Correct Answer:** Hyperkalemia is primarily a feature of **mineralocorticoid (aldosterone) deficiency**, not glucocorticoid deficiency [1]. Aldosterone is responsible for sodium reabsorption and potassium excretion in the distal nephron [1]. In conditions where only glucocorticoids are deficient (such as secondary adrenal insufficiency due to pituitary failure), aldosterone levels remain normal because the Renin-Angiotensin-Aldosterone System (RAAS) is intact [1], [2]. Therefore, potassium levels typically remain within the normal range. **Analysis of Incorrect Options:** * **Weight Loss:** Glucocorticoids are essential for metabolic homeostasis. Deficiency leads to anorexia, nausea, and vomiting, resulting in significant weight loss [2]. * **Fever:** Glucocorticoids have a natural antipyretic effect. Their absence can lead to unexplained low-grade fever or an exaggerated febrile response to minor stimuli [2]. * **Postural Hypotension:** Glucocorticoids are required to maintain vascular tone and "permissiveness" for catecholamine action. Deficiency leads to reduced peripheral vascular resistance and volume depletion, manifesting as postural hypotension [2]. **NEET-PG High-Yield Pearls:** 1. **Hyponatremia** can occur in isolated glucocorticoid deficiency, but it is **dilutional** (due to increased ADH secretion), not due to salt wasting. 2. **Primary Adrenal Insufficiency (Addison’s):** Features hyperkalemia, metabolic acidosis, and hyperpigmentation (due to high ACTH/POMC) [2]. 3. **Secondary Adrenal Insufficiency:** Features normal potassium, no hyperpigmentation (low ACTH), and no metabolic acidosis [2]. 4. **The "Short Synacthen Test"** is the gold standard for diagnosis; an inadequate cortisol rise confirms adrenal insufficiency [2].
Diabetes Mellitus
Practice Questions
Thyroid Disorders
Practice Questions
Adrenal Gland Disorders
Practice Questions
Pituitary Disorders
Practice Questions
Calcium and Bone Metabolism
Practice Questions
Reproductive Endocrinology
Practice Questions
Lipid Disorders
Practice Questions
Endocrine Hypertension
Practice Questions
Multiple Endocrine Neoplasia
Practice Questions
Obesity and Metabolic Syndrome
Practice Questions
Neuroendocrine Tumors
Practice Questions
Endocrine Emergencies
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free